User profiles for Zinnia P. Parra-Guillen
 | Zinnia Patricia Parra GuillénUniversity of Navarra Verified email at unav.es Cited by 580 |
Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically‐Based Modeling
ZP Parra‐Guillen, A Sancho‐Araiz… - Clinical …, 2023 - Wiley Online Library
Oncolytic viruses (OVs) represent a potential therapeutic strategy in cancer treatment. However,
there is currently a lack of comprehensive quantitative models characterizing clinical OV …
there is currently a lack of comprehensive quantitative models characterizing clinical OV …
[HTML][HTML] Mechanistic modeling of a novel oncolytic virus, V937, to describe viral kinetic and dynamic processes following intratumoral and intravenous administration
ZP Parra-Guillen, T Freshwater, Y Cao… - Frontiers in …, 2021 - frontiersin.org
V937 is an investigational novel oncolytic non-genetically modified Kuykendall strain of
Coxsackievirus A21 which is in clinical development for the treatment of advanced solid tumor …
Coxsackievirus A21 which is in clinical development for the treatment of advanced solid tumor …
Pharmacokinetic/pharmacodynamic evaluation of hydrocortisone therapy in pediatric patients with congenital adrenal hyperplasia
J Melin, ZP Parra-Guillen, R Michelet… - The Journal of …, 2020 - academic.oup.com
Objectives Patients with congenital adrenal hyperplasia (CAH) require lifelong replacement
therapy with glucocorticoids. Optimizing hydrocortisone therapy is challenging, since there …
therapy with glucocorticoids. Optimizing hydrocortisone therapy is challenging, since there …
[HTML][HTML] Machine learning analysis of individual tumor lesions in four metastatic colorectal cancer clinical studies: linking tumor heterogeneity to overall survival
Total tumor size (TS) metrics used in TS models in oncology do not consider tumor heterogeneity,
which could help to better predict drug efficacy. We analyzed individual target lesions (…
which could help to better predict drug efficacy. We analyzed individual target lesions (…
Pharmacokinetics and pharmacokinetic–pharmacodynamic relationships of monoclonal antibodies in children
H Edlund, J Melin, ZP Parra-Guillen, C Kloft - Clinical pharmacokinetics, 2015 - Springer
Monoclonal antibodies (mAbs) constitute a therapeutically and economically important drug
class with increasing use in both adult and paediatric patients. The rather complex …
class with increasing use in both adult and paediatric patients. The rather complex …
Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview
ZP Parra-Guillén, G González-Aseguinolaza… - Pharmaceutical …, 2010 - Springer
Since gene therapy started over 20 years ago, more than one-thousand clinical trials have
been carried out. Nonviral vectors present interesting properties for their clinical application, …
been carried out. Nonviral vectors present interesting properties for their clinical application, …
Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies
ZP Parra-Guillen, P Berraondo, E Grenier, B Ribba… - The AAPS journal, 2013 - Springer
Immunotherapy is a growing therapeutic strategy in oncology based on the stimulation of
innate and adaptive immune systems to induce the death of tumour cells. In this paper, we …
innate and adaptive immune systems to induce the death of tumour cells. In this paper, we …
Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer–Proof of concept towards a systems pharmacology approach
H Saafan, S Foerster, ZP Parra-Guillen… - European journal of …, 2016 - Elsevier
… Author links open overlay panel Hisham Saafan a 1 , Sarah Foerster a 1 , Zinnia P. Parra-Guillen
b , Elke Hammer c , Martin Michaelis d , Jindrich Cinatl Jr. e , Uwe Völker c , Holger …
b , Elke Hammer c , Martin Michaelis d , Jindrich Cinatl Jr. e , Uwe Völker c , Holger …
Exploiting pharmacokinetic models of tamoxifen and endoxifen to identify factors causing subtherapeutic concentrations in breast cancer patients
…, R Ter Heine, C Csajka, ZP Parra-Guillen… - Clinical …, 2018 - Springer
… Wicha, Rob ter Heine, Chantal Csajka and Zinnia P. Parra-Guillen declare no conflicts of
interest. Charlotte Kloft reports grants from an industry consortium (AbbVie Deutschland GmbH …
interest. Charlotte Kloft reports grants from an industry consortium (AbbVie Deutschland GmbH …
Role of cytochrome P450 3A4 and 1A2 phenotyping in patients with advanced non‐small‐cell lung cancer receiving erlotinib treatment
ZP Parra‐Guillen, PB Berger… - Basic & clinical …, 2017 - Wiley Online Library
Erlotinib is metabolized by cytochrome p450 ( CYP ) 3A and CYP 1A. This study assessed
CYP 3A4 (midazolam) and CYP 1A2 (caffeine) phenotyping in plasma and dried blood spots ( …
CYP 3A4 (midazolam) and CYP 1A2 (caffeine) phenotyping in plasma and dried blood spots ( …